Objectives: To examine and quantify geographic variation in the initiation of commonly used opioids and prescribed dosage strength among older US nursing home residents.
D
uring the last 2 decades, prescription opioid use in the United States-along with opioid misuse, abuse, and overdosedramatically increased in younger and older adults. [1] [2] [3] The nationwide opioid crisis may be of particular importance in nursing homes, where pain has traditionally been undertreated and longterm opioid use is 2-fold the prevalence documented in older community-dwelling adults. [4] [5] [6] Nationally, extensive geographic variation in opioid prescribing and opioid-related mortality exists, raising concerns about inconsistent and potentially inappropriate prescribing dependent on place. [7] [8] [9] [10] [11] [12] However, the extent to which opioid use varies geographically among older adults living in US nursing homes is unknown.
Opioids are often the preferred approach to pain management for nursing home residents due to the limited availability of safe, effective, and practical alternatives. 13, 14 Yet, little is known about how the most commonly used opioids are initiated in this setting (short-acting oxycodone, hydrocodone, and tramadol). 4 Initial opioid selection may impact the extent to which appropriate pain control and improved physical functioning is achieved, as well as the risk of adverse events (fractures, overdose). This is due to differing pharmacokinetic and pharmacodynamics profiles between opioids including mu opioid receptors affinity, elimination half-lives, and bioavailability. [15] [16] [17] Further, little is known about the initially prescribed dosage strength that residents receive, which may modulate and enhance both the beneficial analgesic effects and risk of adverse opioid-related events. 18 We conducted this study to understand the overall patterns and magnitude of geographic variability in the initiation of commonly used opioids and prescribed dosage strength across states and hospital referral regions (HRRs). We then sought to quantify: (1) the extent to which variation across HRRs could be explained by resident characteristics, facility characteristics, and state; (2) the strength of clustering in opioid prescribing practices within states versus within HRRs; and (3) whether the initial opioid choice was associated with differences in dosage strength in terms of oral morphine equivalents (OMEs). We believed that geographic variation across HRRs may be present due to differing shared beliefs, values, and social networks across regional health care markets, which may affect how opioids are prescribed. 11, 19, 20 Because states and state-specific policies may also influence opioid prescribing, 10, 21 we contrasted variation in opioid prescribing between HRRs and states.
METHODS

Study Design and Data Sources
This study was approved by the University of Massachusetts Institutional Review Board. Using a cross-sectional study design, nursing home residents "entered" the study on the prescription fill date of their first opioid initiation episode (described below). These data to identify and characterize residents were drawn from 4 data sources from 2011: the Minimum Data Set (MDS) 3.0, Medicare (eligibility, Parts B, D), the Certification and Survey Provider Enhanced Reporting (CASPER), and Nursing Home Compare. The MDS is a federally required assessment that is conducted at nursing home admission and 90-day intervals thereafter by nurses who interview residents and their caregivers. Assessments provide information on residents' pain, cognitive and physical functioning, mood, comorbidities, and other measures. [22] [23] [24] Medicare Part B was used to operationalize painful comorbidities recorded in outpatient claims. Part D provided information on opioids and other prescribed medications. We used CASPER, a repository for federally mandated nursing home surveys, to provide information on facility characteristics. Nursing Home Compare, a system developed for consumers to find and compare nursing homes, provided information on facility quality. 25 
Study Sample
Shown in Supplementary Figure 1 (Supplemental Digital Content 1, http://links.lww.com/MLR/B611) we included Medicare beneficiaries (Part A/B/D coverage for ≥ 90 d preceding opioid initiation; no Medicare Advantage) who were long-stay nursing home residents ( ≥ 90 consecutive days in the same facility). We focused on long-stay residents because they generally require long-term assistance to manage their chronic comorbidities. 26 We restricted our sample to residents who were Z65 years or older and initiated a commonly used opioid (oxycodone, hydrocodone, tramadol). 4 Initiation was defined using Part D claims as being prescribed a study opioid with no opioid prescription claim in the preceding 90 days.
We excluded residents who were hospitalized or received skilled nursing facility care (services typically covered by Medicare Part A) during 2011 in the 90 days preceding initiation because medications received during these stays would predominantly be bundled into the Part A per diem rate; therefore, opioid prescriptions during this time would not appear as a Part D claim. We excluded: residents with no MDS assessment in the 90-day lookback period; those living in facilities with no recent CASPER data; residents living in standalone skilled nursing facilities or provider-based facilities (eg, hospital-based long-term care units); those with cancer or receiving hospice care in the year before initiation; those who were comatose; those with any missing data; those initiating implausibly high doses ( > 180 mg OME/d); and those living in small geographic areas (states/districts with <50 residents or HRRs with <30 residents). The final sample size was 62,889 residents.
Opioid Use
Commonly used opioids were short-acting, oral formulations of oxycodone [oxycodone, oxycodone/acetaminophen, oxycodone/ nonsteroidal anti-inflammatory drug (NSAID)], hydrocodone (hydrocodone/acetaminophen, hydrocodone/NSAID), or tramadol (tramadol, tramadol/acetaminophen). These medications are used by > 90% of residents prescribed opioids and may be interchangeably used in nursing homes. 4 From medications dispensed on the index date, we estimated the average daily dose in OME. See Supplementary Table 1, Supplemental Digital Content 1, http:// links.lww.com/MLR/B611, for details on OME and study/nonstudy opioids. 27 We categorized residents prescribed doses ≥ 50 mg OME per day as receiving potentially inappropriately high doses based on recommendations for opioid-naive patients. 18 covered by Part D in 2011, we used the resident's MDS assessment before opioid initiation to classify receipt of anxiolytics or hypnotics in the 7 days before the assessment.
Facility Characteristics
Nursing home facility characteristics are associated with quality of care and may affect prescribing. 32, 33 Using CASPER and Nursing Home Compare, we included the following variables: rural location, facility size, ownership, whether the facility was part of a chain, occupancy, proportion of residents with Medicaid as primary payer, proportion of residents receiving skilled care, proportion of residents with facility-acquired bed sores, proportion of residents restrained, and quartile indicators of the number of minutes per resident day of nursing home staff including registered nurses, physicians, and physician extenders, and overall 5-star rating for nursing home quality measures. See Supplementary 
Analysis
We first conducted crude and stratified descriptive analyses of resident and facility characteristics by opioid initiated. We then categorized the proportion of residents initiating different opioids and doses ≥ 50 mg OME per day into quartiles and generated US maps to visually examine the geographic variation in prescribing by HRR.
We were interested in understanding whether the variation in prescribing observed across HRRs could be explained by resident characteristics, facility characteristics, and state of residence. Thus, we fit multilevel logistic models for each commonly used opioid versus other study opioids (eg, initiating oxycodone vs. hydrocodone or tramadol) and measured between-HRR variation by incorporating HRRs into the model as random intercepts. After fitting random intercept only models for each outcome, we sequentially adjusted for resident characteristics, facility characteristics, and state. 34 Since HRRs can cross state lines ( Fig. 1 ), we fit cross-classified multilevel logistic models with separate random intercepts for HRRs and states for the final model. 35 For adjusted models, we estimated the proportional change in cluster variation (PCV) to quantify the proportion of between-HRR variation that can be explained by covariates in the model. For example, if adjusting for resident characteristics resulted in a PCV of 10.0% for a specific prescribing practice, we would conclude that 10.0% of the geographic variation was due to differences in resident characteristics between HRRs.
We estimated intraclass correlation coefficients (ICC) for all models to understand the strength of clustering within HRRs (ICC HRR ). The ICC HRR measures the correlation among 2 persons chosen at random from within the same HRR. 34 As the ICC increases from 0 towards 1, it indicates that residents within the same HRR have an increased propensity to be prescribed the same opioid. For cross-classified models, we decomposed the variance to separately estimate ICC HRR (ie, the ICC among persons in the same HRR but different states) and ICC state , measuring the strength of clustering for persons in the same states but different HRRs.
To quantify the PCV and ICCs in those initiating doses ≥ 50 mg OME per day versus lower doses, we used the same sequential multilevel modeling strategy as above. To additionally examine the association between specific opioids initiated and prescribed dosage strength, we fit a separate fully adjusted crossclassified model that included specific opioid initiated to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CI). Hydrocodone was chosen as the reference because it was the most commonly initiated study drug. See Methods Appendix, Supplemental Digital Content 1, http://links.lww.com/MLR/B611 for further details.
RESULTS
In 2011, 62,889 long-stay residents initiated opioids (oxycodone, 9.4%; hydrocodone, 56.2; tramadol, 34.5%). These residents lived within 12,345 nursing homes (median residents per home, 4; 25th-75th percentile, 2-7) nested within HRRs (298/306 HRRs; median facilities per HRR, 29; 25th-75th percentile, 16-49); 113 HRRs crossed state lines.
Overall, 53.0% of residents were 85 years and above of age, 75.8% were women, and 82.3% were non-Hispanic white (Table 1; see Supplementary Table 4 , Supplemental Digital Content 1, http://links.lww.com/MLR/B611, for further description of resident and facility characteristics). Nearly 40% and 21.5% had severe cognitive impairment and were physically dependent, respectively. One-third of residents had self-reported or staff-assessed pain, with three-fourth of residents having recorded diagnoses of painful comorbidities from Part B claims. Most residents lived in for-profit facilities (73.1%).
When stratifying by opioid initiated, those initiating tramadol were more commonly women and 85 years and above of age compared with the other initiators. Oxycodone initiators had a lower prevalence of severe cognitive impairment and more self-reported pain on the MDS, as well as painful comorbidities documented in Part B claims than other initiators. Oxycodone initiators were less commonly in facilities that were rural; part of a chain; <80% occupancy; or in the lowest quartiles Physical limitations were defined using the Activities of Daily Living Self-Performance Hierarchy (range, 0-6) to categorize residents as requiring no to limited assistance (0-2), extensive dependence (3-4), or being physically dependent (5-6). of registered nurse, physician, and physician extender staffing relative to other opioid initiators.
Several patterns emerged when examining the crude proportion of specific opioids initiated by HRR. The top quartile of oxycodone initiating HRRs was largely concentrated in Northeast states, which contained 18 of the top 20 prescribing HRRs (Fig. 2A) . Nationally, the proportion of residents initiating oxycodone ranged from 0% (in 28 different HRRs) to 74.5% in Manhattan, NY (5th-95th percentile, 0%-34.7%). Oxycodone was rarely initiated in HRRs within Texas. Alternatively, the top quartile of hydrocodone initiating HRRs largely extended across the middle of the continental US, with prescribing ranging from 3.5% (Bronx, New York) to 90.2% in Redding, CA (5th-95th percentile, 23.9%-81.1%; Fig. 2B ). Tramadol initiation was largely concentrated in Midwest states, Florida, Maryland, and northern New England states (Fig. 2C) , ranging from 5.8% (Alameda County, CA) to 72.1% in Salisbury, MD (5th-95th percentile, 12.0%-53.8%).
The overall proportion of residents initially prescribed doses ≥ 50 mg OME per day was 6.7% with substantial geographic variation (Fig. 3) . The top quartile of initiators prescribed doses ≥ 50 mg OME per day were largely concentrated in western US states. However, many HRRs throughout the continental United States were in the highest quartile of prescribing, and overall, the practice ranged from 0.0% (4 different HRRs) to 27.6% (Boise, ID; 5th-95th percentile, 1.6%-14. Resident and facility characteristics explained 7.5%, 0.2%, −2.5% (ie, an increase in variance), and 9.4% of between-HRR variation for initiating oxycodone, hydrocodone, tramadol, and doses ≥ 50 mg OME per day, respectively (Table 2 ). For initiating oxycodone or doses ≥ 50 mg OME per day, facility characteristics explained a larger proportion of between-HRR variation than resident characteristics. In all cases, adjusting for state of residence resulted in large reductions in between-HRR variation for oxycodone (PCV = 84.1%), hydrocodone (PCV = 58.2%), tramadol (PCV = 59.1%), and initiating doses ≥ 50 mg OME per day (PCV = 46.6%). In fully adjusted cross-classified models, the propensity to initiate oxycodone was more strongly correlated among 2 residents in the same state but different HRRs (ICC state = 0.24) than among residents within the same HRR but different states (ICC HRR = 0.06). These patterns were similar but less pronounced for the propensity to initiate hydrocodone (ICC state = 0.09; ICC HRR = 0.07) and tramadol (ICC state = 0.06; ICC HRR = 0.04). For initiating doses ≥ 50 mg OME per day the ICCs were similar (ICC state = 0.03; ICC HRR = 0.03). In general, resident and facility characteristics were weakly associated with opioid or dose initiated, with > 85% of the aORs between 0.80 and 1.20 (see Supplementary Tables 5, 6 ; Supplemental Digital Content 1, http://links.lww.com/MLR/B611, for further information on effect estimates and Supplementary In fully adjusted cross-classified models that included study drug initiated, being prescribed oxycodone versus hydrocodone was associated with increased odds of being prescribed doses ≥ 50 mg OME per day (aOR, 5.00; 95% CI, 4.57-5.47). Initiating tramadol versus hydrocodone was inversely associated with higher doses (aOR, 0.28; 95% CI, 0.25-0.31).
DISCUSSION
We found that opioid initiation practices among long-stay nursing home residents during 2011 differed from what has been documented in community-dwelling populations, 37, 38 with substantial geographic variation in initiating specific opioids and potentially inappropriate doses In multilevel models, state of residence explained the largest proportion of variation between HRRs, with most opioid prescribing practices more strongly clustered within state than within HRR. Most resident and facility characteristics were weakly associated with prescribing practices in adjusted models. Initiating potentially high inappropriate doses of opioids was associated with choice of starting oxycodone or tramadol versus hydrocodone.
Overall, opioids initiated in nursing homes differ from community settings. Although hydrocodone is initiated similarly across settings, 37, 38 tramadol was prescribed to 34.5% of initiators in nursing homes versus 8.7% and 20.2% of commercially insured and Medicare Advantage initiators, respectively. 38 Conversely, oxycodone was prescribed less frequently to nursing home residents initiating opioids (9.4%) compared with 17%-18.8% of commercially insured and 16.6% of Medicare Advantage initiators. 37, 38 It is unclear how these differences in prescribing affect pain management and safety in nursing homes because most studies exclude nursing home residents and/or compare opioids to placebo rather than conducting head-to-head comparisons of different opioids. 17, [39] [40] [41] That clustering was stronger within states than HRRs and states explained the majority of variation in opioid prescribing practices across HRRs suggests that factors unique to different states-including the implementation and enforcement of laws, policies, and regulations-are strong drivers of how opioids are initiated in this setting. Laws and policies that may have affected prescribing include the implementation of prescription drug monitoring programs, prescription limits restricting the quantity of opioids that can be dispensed, requirements for physician examinations before opioid prescribing, patient identification requirements, pain clinic regulations, and doctor shopping restrictions. 21 These laws varied by state, drastically increased during 2010-2011, 42 and may have affected older nursing home residents even if they were not the primary target of such legislation, as most overdose deaths occur in those below 65 years of age. 3 However, our results must be interpreted cautiously, as it was beyond the scope of the current study to examine the role of specific state policies on opioid prescribing.
We found that the proportion of opioid initiators prescribed oxycodone varied more widely between HRRs than other study drugs, with similar geographic patterns documented in younger disabled Medicare beneficiaries. 11 This may be because oxycodone was the only schedule II drug during 2011 and would have been uniquely affected by state laws such as triplicate prescribing programs which are present in low oxycodone prescribing states such as Texas and California. However, there may be additional important state differences in the number, type, and enforcement of laws intended to curb opioid prescribing. For example, among younger commercially insured adults, rescheduling hydrocodone from schedule III to schedule II in 2014 resulted in a larger reduction of hydrocodone prescribing in Texas than in other states. 43 It is unclear if such legislative changes had the same impact on nursing home residents.
Differences in resident characteristics between HRRs explained little of the observed variation, suggesting that resident characteristics had limited influence on the type and dose of opioid initiated. We are uncertain if such observations are unique to nursing homes because multilevel models have not been used to quantify variation of opioid initiation in other studies. In some cases (being prescribed oxycodone or potentially inappropriate doses), facility characteristics explained a larger proportion of the observed variation than Multilevel logistic models with a random intercept for hospital referral region were sequentially fitted using resident and facility characteristics as described in Supplementary Table 3 (Supplemental Digital Content 1, http://links.lww.com/MLR/B611). The final model was a cross-classified multilevel model including a second random intercept for state. ‡ PCV described the proportional change in HRR variation explained by the multilevel model and was estimated as (variance of random intercept in null modelvariance of random intercept in adjusted model)/variance of random intercept in null model. § ICC HRR estimates the correlation in the propensity to initiate the same opioid or dose between 2 individuals randomly selected from each HRR. The ICC HRR for the final model is an estimate of the correlation between 2 persons in the same HRR but different states.
∥ ICC state was estimated using a cross-classified logistic model and estimates the correlation in the propensity to initiate the same opioid or dose between 2 individuals in the same state but different HRRs. ¶ Adding resident and facility characteristics to this model increased the variance. This can occur when there is negative correlation between the opioid initiated and resident/facility factors within HRRs. 36 HRR indicates hospital referral region; ICC, intraclass correlation coefficient; OME, oral morphine equivalent; PCV, proportional change in cluster variation. resident characteristics. Facility characteristics may affect prescribing directly (eg, increased staffing leading to fewer residents initiating inappropriate doses due to increased oversight) or indirectly through their influence on organizational culture including the shared behaviors, beliefs, values, and assumptions of each facility. 44, 45 Further work is needed, but targeting facility culture may be important for improving opioid prescribing.
Overall, residents initiating opioids had a relatively low prevalence of potentially inappropriate doses (6.7%) in nursing homes compared with commercially insured (19.9%) and Medicare Advantage populations (17.0%). 37 That residents predominantly "start low" may be unsurprising given the high prevalence of frailty and concerns of adverse drug events in nursing homes. 46, 47 Dose also exhibited less clustering within HRRs and states compared with initiating specific opioids, suggesting that the chosen dose may be less regionally driven than specific opioid initiated. However, overall geographic patterns of residents initiating higher doses were in many ways similar to patterns documented in community-dwelling adults. 7, 9, 11 Within the same state and HRR, initiating oxycodone was strongly associated with being prescribed potentially inappropriate doses, whereas tramadol was strongly, inversely associated with higher doses. These findings may be driven by differences in opioid potency, 27 although further contextualizing the relationship between specific opioids and doses is warranted given that many adverse opioid-related events are dose dependent. 18 National efforts to reduce opioid prescribing must not forget that nursing homes have historically undertreated resident pain 5, 6 and have only recently shown potential improvements. 48 In this setting, opioids may often be appropriate because older residents have a high burden of painful comorbidities and lack safe and effective pharmacologic and nonpharmacologic alternatives. 4, 13 Further, nursing homes are medically supervised settings where resident access to medication is mediated through staff, which may limit the risk of adverse opioid-related events. Broader national policy changes must consider this vulnerable population so that the pendulum does not swing back towards undertreating pain.
The strengths of this study include focusing on opioid initiation in an important, understudied population; the national, comprehensive data on facility and resident characteristics; and using multilevel models to examine geographic variation. There are also limitations. Data are from 2011, and opioid legislation is rapidly changing. However, we believe it is unlikely that the strong geographic variation observed in this study could dissipate so rapidly. We had limited data on prescribers. Although we included prescriber staffing levels as facility characteristics, we may not adequately capture prescriber variation in opioid initiation practices. 36, 49 Part B claims provided limited information on severity of painful comorbidities. Yet, we were able to supplement these measures with data from the MDS 3.0, including any self-reported or staff-reported pain, which are not available in traditional claim-based analyses. We assumed that medications were used as prescribed. This is a common assumption 37, 38 but may overestimate our potentially inappropriate dose findings if many initiators use opioids as needed. We did not examine the effects of specific state policies. We had no or limited data on analgesics not typically covered by Part D (acetaminophen, lidocaine, over-the-counter NSAIDS) and whether residents previously used opioids long term. Given our limited follow-up, cross-sectional study design, and focus on resident and facility characteristics, it was beyond the scope of the current study to examine the influence of specific county-level and state-level drivers of opioid initiation. Further work is needed.
Our findings call attention to the complex geographic variation observed by type and dose of opioid initiated in older nursing home residents. The largest driver of observed variation was state of residence, suggesting that state laws, policies, and regulations play the largest role in how opioids are initiated in this setting, although further work is needed to understand how specific laws may affect prescribing in nursing homes. Finally, although the specific opioid initiated was strongly associated with dose and higher doses are associated with increased risks in community-dwelling adults, 18 few studies have examined opioid effectiveness and safety in nursing homes, and further work is needed in these areas to guide clinical decision making.
